Business ❯ Pharmaceutical Industry

Market Trends

Pricing Strategies Drug Pricing Drug Development Drug Sales Novo Nordisk Stock Performance Sales Performance Weight Loss Drugs Competition Investment Drug Approval Drug Competition Generic Drugs Consumer Behavior Sales Projections Revenue Growth Product Launches Celebrity Endorsements Obesity Treatments Investment Opportunities Sales Growth India Digital Solutions Growth Projections Investor Relations Export Decline Challenges Revenue Projections Sales Forecasts Investor Reactions Sales Revenue Sales Data Eli Lilly Clinical Trials Market Supply Chain Price Increase Veterinary Products Drug Accessibility Weight Loss Drug Market Company Performance Illicit Trade Counterfeit Products Weight Loss Treatments Obesity Drugs Stock Analysis Diabetes Medications Investment in Gene Therapy Obesity Market Patent Expiration Drug Efficacy Investment in Healthcare Obesity Treatment Price Adjustments Merck Investment Strategies Company Announcements Drug Production Investor Insights Drug Demand Obesity Drugs Market Investor Sentiment Consumer Genetics Healthcare Costs Obesity Drug Market Drug Adoption Rates Drug Research Drug Shortages Weight-loss Market CBD Market Drug Launches Investment Impact Product Packaging Sustainability Weight Loss Medications Stock Prices Online Pharmacies

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Lilly’s premium price meets a new oral challenger in the GLP‑1 race.

Wegovy Pill Posts Strong U.S. Debut as U.K. Authorizes Higher 7.2 mg Injectable Dose

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Drugmakers to Lift 2026 U.S. List Prices on 350 Branded Medicines

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

FDA Signals Openness to Accelerated Path for Lexeo’s Friedreich’s Ataxia Cardiac Gene Therapy

AstraZeneca Launches U.S. Direct Sales Platform With Farxiga Priced at $182

EU Panel Backs Tezspire for Chronic Rhinosinusitis With Nasal Polyps

Chinese Weight-Loss Drug Suppliers Pivot to Generics as U.S. Crackdown Ends Copycat Boom

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial